Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells $4,119,500.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Krystal Biotech Stock Down 5.6 %

Shares of NASDAQ KRYS opened at $163.64 on Friday. The stock has a market capitalization of $4.71 billion, a price-to-earnings ratio of 92.45 and a beta of 0.80. Krystal Biotech, Inc. has a 52 week low of $107.50 and a 52 week high of $219.34. The firm has a 50-day simple moving average of $181.27 and a 200-day simple moving average of $185.06.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s revenue was up 879.9% on a year-over-year basis. During the same period last year, the company posted ($0.67) EPS. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a research report on Thursday. Citigroup increased their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, December 10th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $206.67.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp increased its stake in shares of Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares during the period. Dimensional Fund Advisors LP increased its position in Krystal Biotech by 1.3% during the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Hood River Capital Management LLC raised its stake in Krystal Biotech by 5.1% during the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock worth $95,694,000 after purchasing an additional 25,507 shares during the period. Finally, Franklin Resources Inc. raised its stake in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).